BridgeMD
New treatment option for Neurodegenerative Diseases
Official title Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
ClinicalTrials.gov ID: NCT05357612
What this study is testing
What is Pimavanserin?
Pimavanserin is an investigational medicine, being studied as a potential treatment for neurodegenerative diseases.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-[18F]MH.MZ in both populations.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 85. Healthy volunteers may be eligible.
You may be able to join if
- Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal...
- Healthy arm - age and gender matched to patient arm
- Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks...
- Study partner available for study visits
You likely can't join if
- Prior stroke or other uncontrolled serious neurological or medical illness
- Contra-indication or inability to tolerate MRI scan
- Use of serotonergic medications in the last 6 weeks
- Incapable of providing independent consent.
- Pregnant or breastfeeding women
- psychosis due to a metabolic, toxic, or primary psychiatric disease
See the full eligibility criteria
- Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
- Healthy arm - age and gender matched to patient arm
- Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
- Study partner available for study visits
- Prior stroke or other uncontrolled serious neurological or medical illness
- Contra-indication or inability to tolerate MRI scan
- Use of serotonergic medications in the last 6 weeks
- Incapable of providing independent consent.
- Pregnant or breastfeeding women
- psychosis due to a metabolic, toxic, or primary psychiatric disease
- Deemed unable to complete neurocognitive testing
- For PD Participants: current or prior use of pimavanserin
- Use of antipsychotics in the last 2 weeks
The study team makes the final eligibility decision.
Where it's taking place
- Nashville, Tennessee, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 85 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nashville, Tennessee, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.